197 related articles for article (PubMed ID: 33597629)
21. Regional differences in perceived oral dryness as determined with a newly developed questionnaire, the Regional Oral Dryness Inventory.
Assy Z; Jager DHJ; Mashhour E; Bikker FJ; Brand HS
Clin Oral Investig; 2020 Nov; 24(11):4051-4060. PubMed ID: 32382921
[TBL] [Abstract][Full Text] [Related]
22. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
23. Submandibular gland-sparing intensity-modulated radiotherapy.
Mendenhall WM; Mendenhall CM; Mendenhall NP
Am J Clin Oncol; 2014 Oct; 37(5):514-6. PubMed ID: 22892434
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
[TBL] [Abstract][Full Text] [Related]
25. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
[TBL] [Abstract][Full Text] [Related]
26. Salivary aquaporin-3 as a screening biomarker for xerostomia in patients with periodontal disease and the effects of xerostomia on oral health-related quality of life.
Atif S; Abdul Wahab N; Ghafoor S; Azlina A; Tauseef A; Rana S; Saeed MQ
PLoS One; 2023; 18(4):e0283995. PubMed ID: 37027451
[TBL] [Abstract][Full Text] [Related]
27. Very late xerostomia, dysphagia, and neck fibrosis after head and neck radiotherapy.
Baudelet M; Van den Steen L; Tomassen P; Bonte K; Deron P; Huvenne W; Rottey S; De Neve W; Sundahl N; Van Nuffelen G; Duprez F
Head Neck; 2019 Oct; 41(10):3594-3603. PubMed ID: 31329343
[TBL] [Abstract][Full Text] [Related]
28. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
[TBL] [Abstract][Full Text] [Related]
29. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis.
Ge X; Liao Z; Yuan J; Mao D; Li Y; Yu E; Wang X; Ding Z
Support Care Cancer; 2020 Jun; 28(6):2701-2712. PubMed ID: 31673782
[TBL] [Abstract][Full Text] [Related]
31. Interventions for the management of dry mouth: non-pharmacological interventions.
Furness S; Bryan G; McMillan R; Worthington HV
Cochrane Database Syst Rev; 2013 Aug; (8):CD009603. PubMed ID: 23996155
[TBL] [Abstract][Full Text] [Related]
32. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
[TBL] [Abstract][Full Text] [Related]
33. Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region.
Porangaba LP; de Melo Garcia F; Rabelo APAA; Andrade AP; de Abreu Alves F; Pellizzon ACA; Jaguar GC
Curr Oncol; 2024 Feb; 31(2):1102-1112. PubMed ID: 38392076
[TBL] [Abstract][Full Text] [Related]
34. Alterations in meibomian glands in patients treated with intensity-modulated radiotherapy for head and neck cancer.
Chen X; Badian RA; Hynne H; Amdal CD; Herlofson BB; Utheim ØA; Westgaard KL; Fineide F; Jensen JL; Utheim TP
Sci Rep; 2021 Nov; 11(1):22419. PubMed ID: 34789830
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the correlation between side effects to oral mucosa, salivary glands, and general health status with quality of life during intensity-modulated radiotherapy for head and neck cancer.
Oba MK; Innocentini LMAR; Viani G; Ricz HMA; de Carvalho Reis T; Ferrari TC; de Macedo LD
Support Care Cancer; 2021 Jan; 29(1):127-134. PubMed ID: 32318870
[TBL] [Abstract][Full Text] [Related]
36. Analysis of factors influencing the development of xerostomia during intensity-modulated radiotherapy.
Randall K; Stevens J; Yepes JF; Randall ME; Kudrimoti M; Feddock J; Xi J; Kryscio RJ; Miller CS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):772-9. PubMed ID: 23523462
[TBL] [Abstract][Full Text] [Related]
37. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients.
Kakoei S; Haghdoost AA; Rad M; Mohammadalizadeh S; Pourdamghan N; Nakhaei M; Bahador M
Arch Iran Med; 2012 Apr; 15(4):214-8. PubMed ID: 22424038
[TBL] [Abstract][Full Text] [Related]
38. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
[TBL] [Abstract][Full Text] [Related]
39. Using multivariate regression model with least absolute shrinkage and selection operator (LASSO) to predict the incidence of Xerostomia after intensity-modulated radiotherapy for head and neck cancer.
Lee TF; Chao PJ; Ting HM; Chang L; Huang YJ; Wu JM; Wang HY; Horng MF; Chang CM; Lan JH; Huang YY; Fang FM; Leung SW
PLoS One; 2014; 9(2):e89700. PubMed ID: 24586971
[TBL] [Abstract][Full Text] [Related]
40. External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy.
Beetz I; Schilstra C; van Luijk P; Christianen ME; Doornaert P; Bijl HP; Chouvalova O; van den Heuvel ER; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):94-100. PubMed ID: 22169766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
